By Gilang Cahya 
Scientists at Duke-NUS Medical School have pinpointed a critical genetic mutation, FBXW7, that renders certain pancreatic and colorectal cancers resistant to Wnt inhibitors, a promising new class of drugs under development. This groundbreaking discovery, published in the esteemed journal Science Advances, not only illuminates a novel therapeutic target but also offers a crucial screening tool to identify patients who will likely not benefit from these therapies once they become clinically available.
The relentless growth of many gastrointestinal cancers is often driven by a hyperactive Wnt signaling pathway, a fundamental biological mechanism governing cell growth and differentiation. In over 80% of colorectal cancers and a significant proportion of pancreatic cancers, this pathway is aberrantly activated, fueling uncontrolled tumor proliferation. Wnt inhibitors, designed to counteract this overactivity, represent a beacon of hope for patients afflicted with these malignancies. Intensive scientific research, including pivotal work at Duke-NUS, has been dedicated to harnessing the potential of these novel therapeutics.
The Challenge of Intrinsic Resistance
"While Wnt inhibitors have demonstrated encouraging results in a subset of patients, our research has revealed an intrinsic resistance mechanism in others," stated Dr. Zhong Zheng, who led the study as a postdoctoral fellow within Duke-NUS’s Cancer & Stem Cell Biology Programme. "Understanding the molecular underpinnings of this resistance is paramount for developing truly personalized treatment strategies, particularly for those patients whose tumors show no response to these drugs."
The research team, comprising Dr. Zhong and Professor David Virshup, the esteemed leader of the Cancer & Stem Cell Biology Programme at Duke-NUS, focused their investigation on colorectal and pancreatic cancers characterized by a hyperactive Wnt pathway. They utilized ETC-159, a Wnt-inhibiting drug whose efficacy had been previously established in preclinical models, to meticulously assess the responsiveness of cancer cells.
FBXW7 Mutation: A Gatekeeper of Resistance
Through a comprehensive analysis of genetic data derived from both drug-responsive and drug-resistant tumors, the scientists made a pivotal discovery: a secondary mutation in the FBXW7 gene confers stubborn resistance to Wnt-blocking drugs. This genetic alteration fundamentally alters the cancer cells’ dependency on the Wnt pathway.
FBXW7 mutations are not an uncommon occurrence, appearing in approximately 15% of colorectal cancers. "The FBXW7 mutations effectively change the fundamental ‘personality’ of the cancer cell," explained Dr. Zhong. "They become indifferent to the Wnt pathway’s signaling, rendering the Wnt inhibitors ineffective in their therapeutic action."
This finding carries profound implications for clinical practice. The ability to test tumors for the presence of FBXW7 genetic mutations could spare numerous patients from undergoing ineffective and potentially toxic treatments. This positions FBXW7 not only as a valuable predictive biomarker but also as a promising target for the development of entirely new therapeutic approaches.
A New Era of Precision Oncology
"The ability to predict drug resistance is a cornerstone of modern precision oncology," emphasized Professor Virshup, the senior author of the study. "Our work elucidates how cancers can circumvent their dependence on Wnt signaling, providing a robust foundation for future therapeutic advancements."
The research opens up exciting avenues for novel treatment strategies. "We can now explore targeting these ‘backup’ pathways that are activated by the FBXW7 mutation to overcome drug resistance," Dr. Zhong elaborated, pointing towards the development of next-generation therapies.
This latest discovery builds upon prior work conducted by the Duke-NUS team, which has also explored mechanisms of resistance in pancreatic cancers. Collectively, these findings significantly deepen our understanding of the diverse and often ingenious ways cancers evolve to ensure their survival and proliferation by finding alternative growth routes.
Expanding the Therapeutic Arsenal
With the identification of more precise therapeutic targets, these discoveries bring the promise of truly personalized cancer therapies closer to realization. Beyond the identification of FBXW7 as a resistance mechanism, the research team observed that tumors exhibiting Wnt inhibitor resistance were surprisingly susceptible to an experimental drug known as dinaciclib. This observation has prompted the next phase of their research, which will involve investigating the potential of dinaciclib, both as a monotherapy and in combination with other agents, for the treatment of these recalcitrant cancers.
"Our ultimate objective is to provide effective treatment options for patients with tumors that exhibit complete resistance," stated Professor Virshup. "By targeting the alternative cancer pathways unleashed by FBXW7 mutations, we aim to translate our fundamental scientific findings into more tailored and potent therapeutic strategies."
Duke-NUS’s Commitment to Translational Research
Professor Patrick Tan, Senior Vice-Dean for Research at Duke-NUS, underscored the significance of this research within the institution’s broader mission. "This study exemplifies the highly translational nature of the basic scientific research conducted at Duke-NUS. Cancers are notoriously diverse, and it is imperative that we can accurately understand and map this diversity to offer truly personalized treatments that are effective for each individual patient. This prevents patients from undergoing unnecessary therapies that are unlikely to yield positive outcomes."
He further added, "This study represents another crucial step in our ongoing journey to transform every cancer into a treatable disease. The dedication of this team embodies our unwavering resolve to deliver more effective therapies to patients worldwide."
Context and Background
The development of Wnt inhibitors has been a significant area of focus in oncology research due to the Wnt pathway’s pervasive role in various cancers. The Wnt signaling cascade is a complex network of proteins that regulates cell-to-cell communication, playing a critical role in embryonic development and tissue homeostasis. However, in many cancers, mutations lead to its dysregulation, promoting uncontrolled cell division and tumor growth.
Colorectal cancer, a leading cause of cancer-related deaths globally, is the second most common cancer diagnosed in both men and women in Singapore. Pancreatic cancer, while less common, is notoriously aggressive and often diagnosed at late stages, making it the 10th most common cause of cancer in men in Singapore. Worldwide, the World Health Organization estimated that over 1.9 million new cases of colorectal cancer were diagnosed in 2020 alone, highlighting the urgent need for effective treatment strategies.
Duke-NUS, in collaboration with Singapore’s Agency for Science, Technology and Research (A*STAR), has been at the forefront of developing novel cancer therapeutics. Notably, they have developed a Singapore-made Wnt inhibitor, ETC-159, which has progressed into early-phase clinical trials, demonstrating the institution’s commitment to translating scientific discoveries into tangible clinical benefits.
Chronology of Discovery
While the precise timeline of the FBXW7 discovery is not explicitly detailed, the research likely involved several stages:
- Initial Observation: Researchers likely observed varying responses to Wnt inhibitors in preclinical models or early clinical trials, prompting an investigation into the underlying causes of resistance.
- Genetic Analysis: Advanced genomic sequencing and comparative analysis of responsive and resistant tumor samples would have been conducted to identify genetic differences.
- Hypothesis Formulation: The identification of recurring mutations in the FBXW7 gene in resistant tumors would have led to the hypothesis that FBXW7 plays a critical role in Wnt inhibitor resistance.
- Functional Validation: Experiments designed to validate the role of FBXW7 mutations in conferring resistance, potentially involving gene editing techniques to introduce or correct FBXW7 mutations in cancer cell lines, would have been performed.
- Drug Susceptibility Testing: Testing the functional impact of FBXW7 mutations on drug sensitivity, including assessing the efficacy of Wnt inhibitors and other experimental agents like dinaciclib, would have been crucial.
- Publication: The culmination of this rigorous scientific process would be the publication of findings in a peer-reviewed journal, such as Science Advances.
Broader Implications for Cancer Treatment
The implications of this research extend far beyond the immediate discovery.
- Personalized Treatment Pathways: The ability to predict Wnt inhibitor response based on FBXW7 status will enable oncologists to stratify patients, ensuring that those most likely to benefit receive the therapy, while others are spared unnecessary treatment and can be directed towards alternative, potentially more effective options.
- Development of Novel Therapies: The identification of FBXW7-mediated resistance opens up a new frontier for drug development. Therapies targeting the alternative signaling pathways that are activated when FBXW7 is mutated could offer a lifeline to patients whose cancers have become refractory to current treatments.
- Biomarker Development: FBXW7 is poised to become a critical biomarker in the clinical management of pancreatic and colorectal cancers, guiding treatment decisions and potentially improving patient outcomes.
- Enhanced Understanding of Cancer Heterogeneity: This study underscores the complex and adaptive nature of cancer, highlighting the importance of understanding the molecular heterogeneity within tumors to overcome treatment resistance.
In conclusion, the work by scientists at Duke-NUS Medical School represents a significant leap forward in our understanding of Wnt inhibitor resistance in pancreatic and colorectal cancers. By unraveling the role of the FBXW7 mutation, they have not only provided a crucial predictive tool for personalized medicine but have also paved the way for the development of innovative therapeutic strategies, bringing us closer to the ultimate goal of making all cancers treatable.
